144 related articles for article (PubMed ID: 35927694)
21. Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study.
Mertz P; Kleinmann JF; Lambert M; Puéchal X; Bonnin A; Boulon C; Diot E; Hachulla E; Harid N; Harle JR; Helder G; Kahn JE; Kone-Paut I; Lavigne C; Magy-Bertrand N; Maillard H; Martin T; Maurier F; Poindron V; Schleinitz N; Sibilia J; Arnaud L
Autoimmun Rev; 2020 Oct; 19(10):102634. PubMed ID: 32801040
[No Abstract] [Full Text] [Related]
22. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
Ansai H; Masuda H; Nakao H; Nishimura N; Kubota M
Pediatr Int; 2022 Jan; 64(1):e15226. PubMed ID: 35831245
[TBL] [Abstract][Full Text] [Related]
23. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients.
Maksimowicz-McKinnon K; Clark TM; Hoffman GS
Arthritis Rheum; 2007 Mar; 56(3):1000-9. PubMed ID: 17328078
[TBL] [Abstract][Full Text] [Related]
24. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.
Tanaka F; Kawakami A; Iwanaga N; Tamai M; Izumi Y; Aratake K; Arima K; Kamachi M; Nakamura H; Huang M; Ida H; Origuchi T; Eguchi K
Intern Med; 2006; 45(5):313-6. PubMed ID: 16596001
[TBL] [Abstract][Full Text] [Related]
25. Clinical study of children with Takayasu arteritis: a retrospective study from a single center in China.
Feng Y; Tang X; Liu M; Zhou J; Zhao X; Li Q
Pediatr Rheumatol Online J; 2017 Apr; 15(1):29. PubMed ID: 28416004
[TBL] [Abstract][Full Text] [Related]
26. Vascular ultrasound for monitoring of inflammatory activity in Takayasu arteritis.
Svensson C; Eriksson P; Zachrisson H
Clin Physiol Funct Imaging; 2020 Jan; 40(1):37-45. PubMed ID: 31605660
[TBL] [Abstract][Full Text] [Related]
27. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F
Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617
[No Abstract] [Full Text] [Related]
28. Takayasu Arteritis Presenting as Unexplained Pulmonary Consolidation: A Case Report.
Koike H; Ashizawa K; Hayashi H; Sakamoto I; Nakamura S; Nishino A; Hayashi T; Uetani M
Vasc Endovascular Surg; 2018 Oct; 52(7):579-582. PubMed ID: 29742991
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study.
Mekinian A; Néel A; Sibilia J; Cohen P; Connault J; Lambert M; Federici L; Berthier S; Fiessinger JN; Godeau B; Marie I; Guillevin L; Hamidou M; Fain O;
Rheumatology (Oxford); 2012 May; 51(5):882-6. PubMed ID: 22223706
[TBL] [Abstract][Full Text] [Related]
30. [Pulmonary cavities with Takayasu arteritis: report of 3 cases and literature review].
Yang PP; Yang YH; Kuang TG; Yang MF; Wang JF; Huang Q; Yang SQ; Li JF; Diao XL; Zhang KN; Gong JN
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):787-792. PubMed ID: 30347551
[No Abstract] [Full Text] [Related]
31. Intravascular ultrasound imaging of isolated and non aorto-ostial coronary Takayasu arteritis: a case report.
Shimizu T; Sato A; Sakamoto K; Seino Y; Kijima M; Matsumoto T; Takeishi Y
BMC Cardiovasc Disord; 2020 Jun; 20(1):260. PubMed ID: 32487208
[TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
33. Reduced aortic elastic properties in a child with Takayasu arteritis: case report and literature review.
Baumgartner D; Sailer-Höck M; Baumgartner C; Trieb T; Maurer H; Schirmer M; Zimmerhackl LB; Stein JI
Eur J Pediatr; 2005 Nov; 164(11):685-90. PubMed ID: 16044277
[TBL] [Abstract][Full Text] [Related]
34. Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study.
Park EH; Lee EY; Lee YJ; Ha YJ; Yoo WH; Choi BY; Paeng JC; Suh HY; Song YW
Rheumatol Int; 2018 Dec; 38(12):2233-2242. PubMed ID: 30229280
[TBL] [Abstract][Full Text] [Related]
35. Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival.
Iniesta Navalón C; Gil Candel M; Salar Valverde I; Nicolás de Prado I; Gómez Espín R; Rentero Redondo L
Rev Esp Enferm Dig; 2021 Nov; 113(11):770-775. PubMed ID: 33486961
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.
Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC
World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174
[TBL] [Abstract][Full Text] [Related]
37. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
[TBL] [Abstract][Full Text] [Related]
38. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients.
Mekinian A; Comarmond C; Resche-Rigon M; Mirault T; Kahn JE; Lambert M; Sibilia J; Néel A; Cohen P; Hie M; Berthier S; Marie I; Lavigne C; Anne Vandenhende M; Muller G; Amoura Z; Devilliers H; Abad S; Hamidou M; Guillevin L; Dhote R; Godeau B; Messas E; Cacoub P; Fain O; Saadoun D;
Circulation; 2015 Nov; 132(18):1693-700. PubMed ID: 26354797
[TBL] [Abstract][Full Text] [Related]
40. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
Alten R; Batko B; Hala T; Kameda H; Radominski SC; Tseluyko V; Babic G; Cronenberger C; Hackley S; Rehman M; von Richter O; Zhang M; Cohen S
RMD Open; 2019; 5(1):e000876. PubMed ID: 30997153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
